Patient Variables Not Linked to Hemoglobin A1c Targets

Share this content:
Patient Variables Not Linked to Hemoglobin A<sub>1c</sub> Targets
Patient Variables Not Linked to Hemoglobin A1c Targets

FRIDAY, July 8, 2016 (HealthDay News) -- Patient variables seem not to be associated with hemoglobin A1c (HbA1c) targets, according to a study published online June 22 in Diabetes Care.

Saeid Shahraz, M.D., Ph.D., from Tufts Medical Center in Boston, and colleagues used data from the National Health and Nutrition Examination Survey to analyze patient-reported HbA1c targets set by physicians and whether there was a correlation between targets and patient characteristics. Data were included for 2,641 individuals with self-reported diabetes, of whom 1,782 responded to a question about HbA1c targets.

The researchers found that 54 percent of respondents reported a target; others reported that they did not know or that no target was set. Only 4 percent of the sample reported target HbA1c >7 percent. Of those reporting that a target was not set, 26 percent were older than 75 years. Of those who were not aware of their target, 70 percent were nonwhite. From 2005 to 2013 there was a decrease in the proportion responding that they did not know their target, from 30 to 10 percent. There were no correlations for variables representing demographics; medical history; biological, physical, and mental health; and health service use with reported target HbA1c.

"The lack of variation with patient characteristics suggests overreliance on a general approach, without consideration of individual variation in the risks and benefits (or patient preference) of tight control," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »